China approves Shanghai Fosun's unit to run human testing for BioNTech's Covid-19 vaccine
The experimental Covid-19 vaccine, BNT162b2, is more than 90% effective based on initial results from large trials outside China, BioNTech's partner Pfizer Inc said on Monday
FILE PHOTO: The headquarters of biopharmaceutical company BioNTech are seen in Mainz, Germany July 31, 2018. REUTERS/Ralph Orlowski
Shanghai Fosun Pharmaceutical Group said on Friday that its unit has received clinical trial approval from China's National Medical Products Administration for a Covid-19 vaccine candidate developed by German firm BioNTech.
The experimental Covid-19 vaccine, BNT162b2, is more than 90% effective based on initial results from large trials outside China, BioNTech's partner Pfizer Inc said on Monday.
Shanghai Fosun said in a company filing that its unit will begin a Phase II clinical trial in China for the candidate when the conditions are ready.
Keep updated, follow The Business Standard's Google news channel
